Streetbeat News

Products Services

NXL

Nexalin Technology Inc. (NASDAQ:NXL) has been awarded a U.S. patent for its noninvasive Deep Intracranial Frequency Stimulation (DIFS) medical device, designed to treat Alzheimer's and other dementia-related brain diseases. The device uses a proprietary frequency-based waveform for pain-free treatment. The global dementia treatment market is projected to grow significantly, and Nexalin's device could revolutionize care for various neurological diseases.

Portfolio Pulse from Vandana Singh

June 20, 2024 | 12:40 pm

AGRI

AgriFORCE CEO Jolie Kahn and Chairman David Welch have issued a letter to shareholders outlining a transformational year for the company in 2024. The company is focusing on innovation in the agriculture industry, including monetizing its RCS systems and Awaken Grains flour, and expanding into the Carbon Credit and Renewable Energy Credit markets. AgriFORCE has reduced its outstanding debentures and announced a $1 million share repurchase program. The company aims to enhance shareholder value through sustainable practices and new technologies, including blockchain.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:39 pm

ALLO

Allogene Therapeutics has initiated a Phase 2 trial (ALPHA3) to investigate Cemacabtagene Ansegedleucel (Cema-cel) as part of the first-line treatment for patients with large B-cell lymphoma (LBCL) likely to relapse. The trial aims to improve cure rates and incorporates Foresight Diagnostics's CLARITY™ test to identify patients with minimal residual disease (MRD). The trial is expected to complete enrollment in the first half of 2026, with a BLA submission anticipated in 2027.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:38 pm

NXL

Nexalin Technology shares are trading higher after being awarded a patent by the USPTO for its deep intracranial frequency stimulation device aimed at treating Alzheimer's and dementia.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:37 pm

FEMY

Femasys shares are trading higher after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:37 pm

ZAPP

Zapp EV shares are trading higher following the company's announcement that it expects first customer deliveries of the i300 in Q4 and anticipates selling over 5,000 units by the fiscal year ending September 30, 2025.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:37 pm

AMPX

Amprius has signed multiple contract manufacturing partnerships to secure over 500 MWh of production capacity for its SiCore offering. This move aims to meet significant customer demand by providing immediate scale-up flexibility without major incremental costs. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:36 pm

NXL

Nexalin Technology has been awarded a patent by the USPTO for its Deep Intracranial Frequency Stimulation device, which is used for the treatment of Alzheimer's and dementia.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:36 pm

CCTG

CCSC Technology International has entered into an international purchase agreement with SHI / LIGHTCARE-SOLUTIONS ApS to manufacture and supply healthcare lighting products.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:35 pm

FEMY

Femasys has received CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products. This approval allows Femasys to market these products in the European Union, potentially expanding its market reach and revenue.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:34 pm